-
Abstract Number: 794
Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma
-
Abstract Number: 795
Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort
-
Abstract Number: 796
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
-
Abstract Number: 797
Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis
-
Abstract Number: 798
Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model
-
Abstract Number: 799
Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital
-
Abstract Number: 800
Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience
-
Abstract Number: 801
Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing
-
Abstract Number: 802
Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial
-
Abstract Number: 803
Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment
-
Abstract Number: 804
STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
-
Abstract Number: 805
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
-
Abstract Number: 806
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
-
Abstract Number: 807
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
-
Abstract Number: 808
Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 198
- Next Page »